All stocks Β· TLL
TL

Trident Lifeline Limited

TLL BSE Pharmaceutical Retailers Healthcare

Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, in…

ISIN INE0MKA01014
Listed β€”
Quarters tracked 13
Filings 8 docs

About

Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. Its products target a range of therapeutic solutions, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental cure, proton pump inhibitor, antiprotozoal, antihistamine, antihypertensive drugs, antiparasitic, antilipidemic drugs, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufacture, trade, and distribution of skin and hair cosmetic products; and medical devices. It exports its products. The company has a strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) for the technology transfer of Vorinostat, a medication for Cutaneous T-Cell Lymphoma (CTCL). Trident Lifeline Limited was incorporated in 2014 and is based in Surat, India.

Quarterly Results

Rs. Crores Β· hover row for definition
Metric Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Sales 26.84 31.97 23.67 27.44 18.82 20.85 16.51 15.66 14.74 18.99 7.09 9.93 8.64
Expenses 19.62 25.24 17.38 21.06 13.89 15.27 12.37 11.24 10.66 16.03 5.61 7.73 6.88
Operating Profit 7.22 6.73 6.29 6.38 4.93 5.58 4.14 4.42 4.08 2.96 1.48 2.20 1.76
OPM % 26.90 21.05 26.57 23.25 26.20 26.76 25.08 28.22 27.68 15.59 20.87 22.16 20.37
Other Income 0.53 1.64 0.89 1.11 0.54 1.61 0.54 0.52 0.47 1.26 0.25 0.38 0.33
Depreciation 0.70 0.04 0.71 0.59 0.51 0.71 0.38 0.16 0.33 0.19 0.19 0.16 0.13
Interest 0.49 0.38 0.54 0.42 0.33 0.46 0.35 0.27 0.20 0.14 0.15 0.11 0.10
Profit before tax 6.56 7.95 5.93 6.48 4.63 6.02 3.95 4.51 4.02 3.89 1.39 2.31 1.86
Tax % 23.48 28.81 32.21 23.77 24.84 27.57 23.29 24.83 25.12 37.02 20.86 25.97 24.73
Net Profit 5.02 5.66 4.01 4.94 3.48 4.35 3.03 3.39 3.01 2.45 1.11 1.71 1.40
EPS in Rs 4.21 4.74 3.36 4.26 3.03 3.78 2.63 2.95 2.62 2.13 0.97 1.49 1.22

Profit & Loss

Annual Β· Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Sales 102.0068.0045.0032.0022.0010.005.00
Expenses 78.0050.0036.0025.0019.008.005.00
Operating Profit 24.0018.009.006.003.001.000.00
OPM % 24.0026.0020.0020.0012.0013.00-5.00
Other Income 4.003.002.001.001.000.000.00
Interest 2.001.001.000.000.000.001.00
Depreciation 2.002.001.000.000.000.000.00
Profit before tax 25.0018.0010.007.003.001.00-1.00
Tax % 28.0027.0028.009.00-32.0026.00-26.00
Net Profit 18.0013.007.006.004.001.00-1.00
EPS in Rs 15.1611.356.125.234.941.26-2.58
Dividend Payout % 0.000.000.000.000.000.000.00

Balance Sheet

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Equity Capital 12.0012.0012.0012.008.005.003.00
Reserves 87.0054.0041.0034.00-3.00-5.00-6.00
Borrowings 25.0015.006.003.002.005.006.00
Other Liabilities 36.0017.0014.007.007.007.003.00
Total Liabilities 159.0098.0073.0056.0014.0011.006.00
Fixed Assets 29.0015.008.003.001.001.001.00
CWIP 0.001.004.000.000.000.000.00
Investments 20.0012.004.004.000.000.000.00
Other Assets 111.0070.0057.0049.0012.0010.006.00
Total Assets 159.0098.0073.0056.0014.0011.006.00

Cash Flows

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Cash from Operating Activity 8.00-3.001.00-17.000.001.00-1.00
Cash from Investing Activity -20.00-8.00-11.00-6.000.00-1.000.00
Cash from Financing Activity 14.007.002.0036.001.00-1.001.00
Net Cash Flow 2.00-4.00-8.0014.000.000.000.00
Free Cash Flow -7.00-9.00-8.00-19.00-1.001.00-1.00
CFO/OP % 57.004.0037.00-256.00-7.00118.00219.00

Ratios

Annual Β· Days / % β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Debtor Days 177.00110.00112.00140.0083.0024.0097.00
Inventory Days 136.00167.00137.00129.0095.00349.00104.00
Days Payable 153.0097.0094.0087.00134.00266.00202.00
Cash Conversion Cycle 160.00180.00155.00183.0044.00107.00-1.00
Working Capital Days 192.00226.00246.00274.0049.0012.00-12.00
ROCE % 26.0028.0019.0025.0055.0034.00β€”

Shareholding Pattern

% holding β€” latest first
Holder Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 62.59 62.86 64.11 63.10 63.04 63.04 62.99 62.99 65.50 67.48 70.04 70.04
FIIs 5.25 7.24 7.04 7.71 7.21 6.62 6.09 6.09 6.02 6.02 4.64 4.64
DIIs 0.26 0.27 0.35 0.41 0.39 0.09 0.00 0.00 0.00 0.00 0.00 0.00
Public 31.90 29.64 28.50 28.77 29.35 30.25 30.92 30.93 28.47 26.49 25.31 25.31
No. of Shareholders 709 607 575 554 549 534 523 507 502 500 481 439

Corporate Actions

No corporate actions recorded.

Announcements

5 filings